File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.pcd.2022.01.005
- WOS: WOS:000813410400002
Supplementary
-
Citations:
- Web of Science: 0
- Appears in Collections:
Article: Metabolic dysfunction-associated fatty liver disease — How relevant is this to primary care physicians and diabetologists?
Title | Metabolic dysfunction-associated fatty liver disease — How relevant is this to primary care physicians and diabetologists? |
---|---|
Authors | |
Issue Date | 2022 |
Citation | Primary Care Diabetes, 2022, v. 16, p. 245-251 How to Cite? |
Abstract | Abstract Metabolic-dysfunction associated fatty liver disease (MAFLD) is a newly introduced entity hoping to more precisely define fatty liver disease. Despite the controversies surrounding MAFLD, the definition is getting more widely accepted by the global liver-health community. MAFLD represents a cohort of patients enriched with more advanced liver disease, cardio-renal and metabolic complications with increased mortality. This review aims to provide all primary care physicians and diabetologists with a clinical management update from a non-hepatologist's perspective, and a summary of important findings from recent studies to raise disease awareness and highlight the relevance of MAFLD to their daily clinical practice. |
Persistent Identifier | http://hdl.handle.net/10722/322536 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, CHP | - |
dc.date.accessioned | 2022-11-14T08:26:00Z | - |
dc.date.available | 2022-11-14T08:26:00Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Primary Care Diabetes, 2022, v. 16, p. 245-251 | - |
dc.identifier.uri | http://hdl.handle.net/10722/322536 | - |
dc.description.abstract | Abstract Metabolic-dysfunction associated fatty liver disease (MAFLD) is a newly introduced entity hoping to more precisely define fatty liver disease. Despite the controversies surrounding MAFLD, the definition is getting more widely accepted by the global liver-health community. MAFLD represents a cohort of patients enriched with more advanced liver disease, cardio-renal and metabolic complications with increased mortality. This review aims to provide all primary care physicians and diabetologists with a clinical management update from a non-hepatologist's perspective, and a summary of important findings from recent studies to raise disease awareness and highlight the relevance of MAFLD to their daily clinical practice. | - |
dc.language | eng | - |
dc.relation.ispartof | Primary Care Diabetes | - |
dc.title | Metabolic dysfunction-associated fatty liver disease — How relevant is this to primary care physicians and diabetologists? | - |
dc.type | Article | - |
dc.identifier.email | Lee, CHP: pchlee@hku.hk | - |
dc.identifier.authority | Lee, CHP=rp02043 | - |
dc.identifier.doi | 10.1016/j.pcd.2022.01.005 | - |
dc.identifier.hkuros | 341506 | - |
dc.identifier.volume | 16 | - |
dc.identifier.spage | 245 | - |
dc.identifier.epage | 251 | - |
dc.identifier.isi | WOS:000813410400002 | - |